Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1636 1645 1651 1656
This examiner grants 33% of resolved cases
Delphinus Dou Yi Yu works in Art Unit 1634 of Tech Center 1600. With 6 resolved cases, the examiner has an allowance rate of 33.3 percent. The median days to allowance is 1026. The 33.3 percent allowance rate suggests a challenging environment with a low probability of success for applicants in this unit.
The interview lift is 0.0 percent. These metrics, based on 6 resolved cases, indicate a pendency of 1026 days, which is nearly three years. The 0.0 percent interview lift indicates that interviews have not yet been shown to improve the probability of success for this examiner. Practitioners should focus on high-quality written responses to navigate the prosecution process. With 6 resolved cases, the data provides an initial look at the examiner's patterns. The 1026-day median pendency is a significant factor to consider when planning a strategy. Applicants should be aware that the 33.3 percent baseline is difficult to overcome through standard procedures. The zero lift suggests that verbal communication has not impacted outcomes.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18474969 | ADENOSINE DEAMINASE VARIANTS AND USES THEREOF | Non-Final OA | Beam Therapeutics Inc. |
| 18452127 | HIGH-THROUGHPUT METHODS FOR ANALYZING AND AFFINITY-MATURING AN ANTIGEN-BINDING MOLECULE | Non-Final OA | 10x Genomics, Inc. |
| 18496554 | Splicing Modulators for the Treatment of Timothy Syndrome | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17909341 | Artificial Chromosome Vector and Use Thereof | Final Rejection | The University of Tokyo |
| 18254027 | TRNA FRAGMENTS AND METHODS OF USE | Non-Final OA | Thomas Jefferson University |
| 18525922 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18236437 | PRION PROTEIN (PRNP) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18570967 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEMOGLOBINOPATHIES | Non-Final OA | Duke University |
| 18520481 | PROTACS WITH TRANSCRIPTION FACTOR TARGETING MOIETIES | Non-Final OA | Icahn School of Medicine at Mount Sinai |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy